Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04757571
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-01
First Post:
2021-02-12
Brief Title:
The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients
Sponsor:
Sadat City University
Organization:
Sadat City University
Study Overview
Official Title:
The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients A Proof-of-Concept Randomized Double-Blind Placebo-Controlled Trial
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Among three MAPK families paroxetine was found to be able to decrease the phosphorylation of ERK It was reported that paroxetine attenuates the symptoms of collage induced arthritis rats due to its inhibitory effect on T cell activation and infiltration to synovial tissue via suppression of ERK pathway This study aimed to evaluate the therapeutic efficacy of paroxetine in rheumatoid arthritis Paroxetine prevents the joint inflammation which is at the very early stage paroxetine could inhibit GRK2 with selectivity over other GRKs Medications developed for maintaining the immunologic equilibrium such as GRK2 inhibitors will be the novel trends in RA treatment that could avoid the adverse side effects that are common with current treatment options
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None